ublituximab + umbralisib + venetoclax

A **three-drug combination** therapy consisting of the monoclonal antibody ublituximab, the PI3K-δ inhibitor umbralisib, and the BCL-2 inhibitor venetoclax. This regimen is designed for patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including those with high-risk genetic features and resistance to prior Bruton tyrosine kinase (BTK) inhibitors. Ublituximab targets and depletes B-cells via CD20 binding; umbralisib inhibits phosphatidylinositol-3-kinase delta and casein kinase 1 epsilon, impacting B-cell signaling and survival; venetoclax selectively inhibits BCL-2, promoting apoptosis in leukemia cells. The combination aims to achieve deep remissions and high rates of undetectable minimal residual disease (uMRD), using a time-limited, response-adapted approach to minimize toxicity and maximize efficacy[1][3][5][7][9].

Brand names

Briumvi (ublituximab)Ukoniq (umbralisib)Venclexta (venetoclax)

Other names

U2-VeNU-2-VeNU 2-VeNUUVublituximab + umbralisib + venetoclax